Last reviewed · How we verify

NCT05351125: CHD

Outcomes Of Interventional Catheterization In Infants Less Than 3 Months With Critical Congenital Heart Disease

Status unknown Last updated 28 April 2022
What this trial tests

trial testing cardiac catheterization in Critical Congenital Heart Disease in 40 participants. Status unknown.

Timeline
28 June 2022
Primary endpoint
30 December 2023
30 December 2024

Quick facts

Lead sponsorYHAlattar
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment40
Start date28 June 2022
Primary completion30 December 2023
Estimated completion30 December 2024

Drugs / interventions tested

Conditions studied

Sponsor

YHAlattar

Who can join

Adults 12 Hours to 3 Months, any sex, with Critical Congenital Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Congenital heart disease is the most common birth defect affecting mostly 1 in 100 births(1), critical congenital heart disease is when there is low systemic cardiac output which requires urgent surgery or catheter intervention in the first year of life(2), in low-income countries CCHD is associated with severe high mortality rate due to low health resources, in high-income countries, CCHD is associated with life-long morbidities and a high burden on the health care systems(1-3)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of cardiac catheterization

Trials testing the same drug.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05351125.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing